Orgenesis, a global biotech company focused on cell and gene therapies (CGTs), and Cure Therapeutics, a developer of immuno-oncology and cell and gene therapies to target cancer and infectious diseases, signed a joint venture agreement.

The JV aims to advance the development, regulatory and commercialization of point of care production for both organizations’ cell and gene therapies and immunotherapies.

The companies will collaborate on developing and commercializing Cure Therapeutics’ pipeline on a global basis, as well as developing, commercializing and supplying Orgenesis’ therapeutic pipeline in South Korea and Japan. In connection with the agreement, each of Cure Therapeutics and Orgenesis will contribute at least $10 million to the joint venture to cover operating costs, $5 million of which may be provided in the form of in-kind contribution.

The first focus of the partnership will be aligning the efforts of both companies to advance proprietary Orgenesis CAR-T, TILS and DUVAC therapies into clinical trials in South Korea and Japan. Process development and validation will be completed by leveraging the POCare Technologies from the Orgenesis platform to achieve automated manufacturing at the point of care.